Related Experiment Video
Updated: Jun 13, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori
Yu-Cheng Zhu1, Keng Li1, Anjiang Sun2
1Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
Background:
Resistance to antibiotics has resulted in the effectiveness of conventional eradication therapies for Helicobacter pylori being reduced, creating a need for regimens that are effective, safe, and simple. In this study, we evaluated the eradication efficacy, adverse events, and medication adherence of four different tegoprazan-based regimens administered as first-line therapy for H. pylori infection. We also explored the clinical value of adding bismuth to a triple therapy regimen.
Methods:
In this prospective, randomized controlled trial, 640 treatment-naive patients with confirmed H. pylori infection were randomly assigned to one of the four groups undergoing 14-day treatment regimens of tegoprazan-amoxicillin (TA), tegoprazan-tetracycline (TT), tegoprazan-amoxicillin-tetracycline (TAT), or tegoprazan-amoxicillin-tetracycline-bismuth (TATB), with 160 patients in each group. The outcomes were the eradication rate, incidence of adverse events, and medication adherence.
Results:
In the intention-to-treat analysis, the H. pylori eradication rates in the TA, TT, TAT, and TATB groups were 80.0% (95% confidence interval [CI]: 73.0-85.9), 61.9% (95% CI: 53.9-69.4), 93.1% (95% CI: 88.0-96.5), and 89.4% (95% CI: 83.5-93.7), respectively. Compared with the TATB regimen, the TAT regimen was non-inferior (95% CI, -3.9% to 11.5%; non-inferiority p < 0.001), whereas demonstrating non-inferiority in the TA and TT regimens failed. Adverse events were less frequent in the TA (10.6%), TT (17.5%), and TAT (20.0%) groups than in the TATB group (36.9%; all p < 0.001). Medication adherence was high across groups, with no significant between-group differences observed.
Conclusions:
High eradication efficacy was demonstrated for the TAT regimen; this regimen was non-inferior to the TATB regimen, and it was associated with fewer adverse events. These findings suggest that it may be an effective first-line treatment option for H. pylori infection.
Trial Registration:
ClinicalTrials.gov identifier: NCT06977841.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:24Peptic Ulcer Disease II: Pathophysiology
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.